PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Tirzepatide Cuts Major Kidney Events 23% Versus Dulaglutide in SURPASS-CVOT

tirzepatidedulaglutideGIP/GLP-1 receptor agonisttype 2 diabeteschronic kidney diseasealbuminuriaeGFRSURPASS-CVOTcardiovascular outcomes trialexploratory analysisnephrology Nephrology

Background Information

Tirzepatide outshines dulaglutide in kidney protection for diabetes.

Tirzepatide shows potential to better manage kidney outcomes in people with type 2 diabetes compared to dulaglutide. Tirzepatide reduced the risk of major kidney events by 23% compared to dulaglutide and slowed decline in eGFR. Findings suggest tirzepatide may be preferable for kidney protection in type 2 diabetes, but gastrointestinal side effects were more common. Tirzepatide may offer greater kidney protection than dulaglutide in diabetes.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Zoungas S, D'Alessio D, Pavo I, Bhatt DL, Buse JB, Prato SD, Kahn SE, Lincoff AM, McGuire DK, Nauck MA, Nissen SE, Sattar N, Zinman B, Ceriello A, Stechemesser L, Verhaegen A, Broder JC, Wolfe R, Miller D, Nishiyama H, Wang X, Weerakkody G, Wiese RJ, Nicholls SJ

Citation: Zoungas S, D'Alessio D, Pavo I, et al. A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial. The lancet. Diabetes & endocrinology. 2026;14(7):544-557. doi:10.1016/S2213-8587(26)00032-X

Article Links: PubMed · Journal / DOI

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.